Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Powles on Durvalumab in Urothelial Cancer

Thomas Powles, MD
Published: Monday, Feb 20, 2017



Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1–negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.
 


Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1–negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x